< Back to previous page

Project

Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPT (HepatoSCRIPT)

Approximately 400 million adults are obese worldwide. Non-alcoholic fatty liver disease (NAFLD), a consequence of obesity, is becoming a leading cause of hepatocellular carcinoma (HCC) in high-income countries. Despite the increasing incidence of NAFLD-related HCC, we cannot yet distinguish the patients that will progress to HCC from those that will not. The consortium represents a unique opportunity to integrate our knowledge and expertise in one strategic project. In HepatoSCRIPT, we will assess genetic, proteomic, metabolic and immune profiles of obese patients with and without HCC at single cell resolution and integrate these to develop risk biomarker profiles. Moreover, following their identification, candidate pathways and mechanisms will be investigated as potential therapeutic targets for obesity-induced HCC, enabling the development of novel therapeutic strategies for HCC patients. Thus, HepatoSCRIPT is a multidisciplinary study integrating beyond state-of-the-art data to deliver risks profiles for the early diagnosis and treatment of obesity-related HCC.

Date:1 Jan 2023 →  Today
Keywords:Non-alcoholic fatty liver disease, obesity, hepatocellulair carcinoom (HCC), risk biomarker profiles
Disciplines:Cancer prevention, Cancer diagnosis